EXHIBIT 99.1


                  SIMULATIONS PLUS ANNOUNCES ANOTHER MULTI-YEAR
                         PHARMACEUTICAL SOFTWARE LICENSE

        SALE CONTRIBUTES TO NEW RECORD FOR SECOND FISCAL QUARTER REVENUES

         LANCASTER, CA, FEBRUARY 27, 2004. Simulations Plus, Inc. (OTCBB: SIMU),
the leading provider of ADME absorption simulation and neural net
structure-to-property prediction software for pharmaceutical discovery and
development, today announced that a global pharmaceutical company has signed a
multi-year global software license agreement. The first multi-year global
license by a large pharmaceutical company was announced by the Company in the
fourth quarter of its previous fiscal year in August 2003. Neither customer has
agreed to be identified.

         Ron Creeley, vice president of marketing and sales for Simulations Plus
and the company's Words+ subsidiary, said, "We're pleased to announce another
multi-year license agreement for Simulations Plus software. Because this
two-year license covers only a portion of our software offerings for the
customer's multiple research sites, we believe that we still have the
opportunity to license additional software to this customer during the two-year
period. As we have noted earlier, we continue to pursue multi-year global
license agreements with other large pharmaceutical customers as one part of our
growth strategy."

         Momoko Beran, chief financial officer for Simulations Plus, added,
"This license, added to our other pharmaceutical software license sales for the
quarter, as well as improved sales for our Words+ subsidiary over last year's
second quarter, is expected to result in another record for second quarter
revenues. Preliminary figures indicate an increase in revenues of approximately
18% over last year's second quarter." The Company's second fiscal quarter ends
on February 29.

ABOUT SIMULATIONS PLUS, INC.

Simulations Plus, Inc., is a premier developer of groundbreaking drug discovery
and development simulation software, which is licensed to and used in the
conduct of drug research by major pharmaceutical and biotechnology companies
worldwide. The Company has two other businesses, Words+, Inc. and FutureLab(TM),
which are based on its proprietary software technologies. Simulations Plus,
Inc., is headquartered in Southern California and trades on the OTCBB under the
symbol "SIMU." For more information, visit our Web site at
www.simulations-plus.com.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995
- With the exception of historical information, the matters discussed in this
press release are forward-looking statements that involve a number of risks and
uncertainties. The actual future results of the Company could differ
significantly from those statements. Factors that could cause or contribute to
such differences include, but are not limited to: the ability of the Company to
book revenues and earnings as it expects for the current quarter, the ability of
the Company to maintain its competitive advantage, the general economics of the
pharmaceutical industry, the ability of the Company to attract and retain
sufficient scientific and technical staff to sustain its R&D and customer
support functions, and a sustainable market. Further information on the
Company's risk factors is contained in the Company's quarterly and annual
reports as filed with the Securities and Exchange Commission.

                                       ###


                                       5